| First Author | Stark AK | Year | 2018 |
| Journal | Nat Commun | Volume | 9 |
| Issue | 1 | Pages | 3174 |
| PubMed ID | 30093657 | Mgi Jnum | J:265645 |
| Mgi Id | MGI:6201788 | Doi | 10.1038/s41467-018-05674-8 |
| Citation | Stark AK, et al. (2018) PI3Kdelta hyper-activation promotes development of B cells that exacerbate Streptococcus pneumoniae infection in an antibody-independent manner. Nat Commun 9(1):3174 |
| abstractText | Streptococcus pneumoniae is a major cause of pneumonia and a leading cause of death world-wide. Antibody-mediated immune responses can confer protection against repeated exposure to S. pneumoniae, yet vaccines offer only partial protection. Patients with Activated PI3Kdelta Syndrome (APDS) are highly susceptible to S. pneumoniae. We generated a conditional knock-in mouse model of this disease and identify a CD19(+)B220(-) B cell subset that is induced by PI3Kdelta signaling, resides in the lungs, and is correlated with increased susceptibility to S. pneumoniae during early phases of infection via an antibody-independent mechanism. We show that an inhaled PI3Kdelta inhibitor improves survival rates following S. pneumoniae infection in wild-type mice and in mice with activated PI3Kdelta. These results suggest that a subset of B cells in the lung can promote the severity of S. pneumoniae infection, representing a potential therapeutic target. |
